179 results on '"Deben, Christophe"'
Search Results
2. Auranofin repurposing for lung and pancreatic cancer: low CA12 expression as a marker of sensitivity in patient-derived organoids, with potentiated efficacy by AKT inhibition
3. CRISPR/Cas9-edited ROS1 + non-small cell lung cancer cell lines highlight differential drug sensitivity in 2D vs 3D cultures while reflecting established resistance profiles
4. IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts
5. Model Systems in Plasma Biomedicine
6. “Keep on ROCKIn”: Repurposed ROCK inhibitors to boost corneal endothelial regeneration
7. A systematic review of patient-derived tumor organoids generation from malignant effusions
8. OrBITS: label-free and time-lapse monitoring of patient derived organoids for advanced drug screening
9. Single-organoid analysis reveals clinically relevant treatment-resistant and invasive subclones in pancreatic cancer
10. Cellular senescence in cancer: clinical detection and prognostic implications
11. Auranofin reveals therapeutic anticancer potential by triggering distinct molecular cell death mechanisms and innate immunity in mutant p53 non-small cell lung cancer
12. Patient-derived organoids as individual patient models for chemoradiation response prediction in gastrointestinal malignancies
13. The potential and controversy of targeting STAT family members in cancer
14. Capturing the heterogeneity of the pancreatic ductal adenocarcinoma tumor microenvironment: novel triple co-culture spheroids for drug screening and angiogenic evaluation
15. Advancements in Research and Treatment Applications of Patient-Derived Tumor Organoids in Colorectal Cancer.
16. Endogenous antioxidants in the prognosis and treatment of lung cancer
17. Contributors
18. APR-246 (PRIMA-1MET) strongly synergizes with AZD2281 (olaparib) induced PARP inhibition to induce apoptosis in non-small cell lung cancer cell lines
19. TP53 and MDM2 genetic alterations in non-small cell lung cancer: Evaluating their prognostic and predictive value
20. UAS™—A Urine Preservative for Oncology Applications
21. Phototoxicity and Cell Passage Affect Intracellular Reactive Oxygen Species Levels and Sensitivity Towards Non-Thermal Plasma Treatment in Fluorescently-Labeled Cancer Cells
22. Auranofin Synergizes with the PARP Inhibitor Olaparib to Induce ROS-Mediated Cell Death in Mutant p53 Cancers
23. Uncovering the hidden threat: single-organoid analysis reveals clinically relevant treatment-resistant and invasive subclones in pancreatic cancer
24. Urine biomarkers in cancer detection: A systematic review of preanalytical parameters and applied methods
25. Functional Validation of the Putative Oncogenic Activity of PLAU
26. Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis
27. OrBITS: label-free and time-lapse monitoring of patient derived organoids for advanced drug screening
28. Optimization of the Solvent and In Vivo Administration Route of Auranofin in a Syngeneic Non-Small Cell Lung Cancer and Glioblastoma Mouse Model
29. Expression of SARS-CoV-2-Related Surface Proteins in Non-Small-Cell Lung Cancer Patients and the Influence of Standard of Care Therapy
30. Prognostic implications of cellular senescence in resected non-small cell lung cancer
31. Functional Validation of the Putative Oncogenic Activity of PLAU.
32. Chapter 4 - Endogenous antioxidants in the prognosis and treatment of lung cancer
33. Auranofin and Cold Atmospheric Plasma Synergize to Trigger Distinct Cell Death Mechanisms and Immunogenic Responses in Glioblastoma
34. OrBITS: Label-free and time-lapse monitoring of patient derived organoids for advanced drug screening
35. Cancer-Associated Fibroblasts as a Common Orchestrator of Therapy Resistance in Lung and Pancreatic Cancer
36. Characterization of acquired nutlin-3 resistant non-small cell lung cancer cells
37. Oxidative Stress-Inducing Anticancer Therapies: Taking a Closer Look at Their Immunomodulating Effects
38. Abstract 2962: Molecular mechanisms underlying the sensitizing effect of mutant p53 protein expression for Auranofin treatment of NSCLC and PDAC cells
39. Mass Spectrometry Imaging Reveals Neutrophil Defensins as Additional Biomarkers for Anti-PD-(L)1 Immunotherapy Response in NSCLC Patients
40. Radiosensitization of Non-Small Cell Lung Cancer Cells by the Plk1 Inhibitor Volasertib Is Dependent on the p53 Status
41. Cold Atmospheric Plasma-Treated PBS Eliminates Immunosuppressive Pancreatic Stellate Cells and Induces Immunogenic Cell Death of Pancreatic Cancer Cells
42. In vitro study of the Polo‐like kinase 1 inhibitor volasertib in non‐small‐cell lung cancer reveals a role for the tumor suppressor p53
43. Hypoxia-Induced Cisplatin Resistance in Non-Small Cell Lung Cancer Cells Is Mediated by HIF-1α and Mutant p53 and Can Be Overcome by Induction of Oxidative Stress
44. Unveiling a CD70-positive subset of cancer-associated fibroblasts marked by pro-migratory activity and thriving regulatory T cell accumulation
45. Immunogenic Potential Of Cold Atmospheric Plasma For The Treatment Of Pancreatic Cancer
46. Gaining Insight In The Selectivity And Plasma-Liquid Chemistry For Plasma Treatment Of Cancer
47. Targeting the p53 pathway in non-small cell lung cancer : preclinical study on combination startegies in both <tex>TP53^{WildType}$</tex> and <tex>TP53^{Mutant}$</tex> tumors
48. Poly(I:C) primes primary human glioblastoma cells for an immune response invigorated by PD-L1 blockade
49. Abstract 1056: Volasertib in combination with radiotherapy: The perfect match in non-small cell lung cancer
50. Preclinical data on the combination of cisplatin and anti-CD70 therapy in non-small cell lung cancer as an excellent match in the era of combination therapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.